Drug Lag Debate In China Expands Beyond Industry, Regulator Corridors
This article was originally published in PharmAsia News
Executive Summary
Access to innovative drugs in China lags developed markets by a considerable margin with well repeated industry assertions that the root cause is a slow regulatory approval process. But a well-known writer in China for the weekly popular magazine, Life Week, has also highlighted the issue, bringing it some mass attention as patients question why they cannot get some of the latest treatments at home.